Meningococcal Meningitis Clinical Trial
Official title:
A Randomized, Blinded, Peer-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector) in a Population Aged 18-59 Years
This is a randomized, observer-blind, peer-controlled study. There will be 2 treatment groups, screened subjects were given study numbers in the order of enrollment and randomly assigned to the test and control groups in a 1:1 ratio. Subjects were required to complete a 1-dose immunization program with 0.5 ml of vaccine in both the test and control groups.
Status | Not yet recruiting |
Enrollment | 840 |
Est. completion date | October 2024 |
Est. primary completion date | October 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 59 Years |
Eligibility | Inclusion Criteria: - 18~59 years old at the time of screening. - Should not have received any meningococcal vaccine in the last 3 years. - Volunteers have given informed consent, have voluntarily signed an informed consent form, are able and willing to comply with the requirements of the clinical trial protocol, and are able to complete the 180-day study follow-up visit. - Volunteers have given informed consent, have voluntarily signed an informed consent form, are able and willing to comply with the requirements of the clinical trial protocol, and are able to complete the 180-day study follow-up visit. - Willingness to discuss medical history with the investigator or physician and to allow access to all medical records relevant to this trial. Exclusion Criteria: - Fever before vaccination, axillary temperature >37.0°C. - History of epilepsy, convulsions or seizures or history or family history of psychiatric disorders. - Volunteers with current meningitis or a history of meningitis. - Blood pregnancy-positive or breastfeeding women with a planned pregnancy within 180 days of the volunteer or her partner. - Hypersensitivity to an ingredient or excipient of the medicinal product used in this clinical trial (mainly: group A meningococcal podophyllotoxin, group C meningococcal podophyllotoxin, group Y meningococcal podophyllotoxin, group W135 meningococcal podophyllotoxin, sucrose, mannitol, sodium chloride, dipotassium hydrogen phosphate trihydrate, potassium dihydrogen phosphate). - Severe hypertension uncontrolled by medication (at on-site measurement: systolic blood pressure = 160 mmHg, diastolic blood pressure = 100 mmHg). - Previous vaccination-related hospitalizations or emergencies. - Bleeding constitution or condition associated with prolonged bleeding that investigators consider contraindicated for intramuscular injection. - Other vaccinations within 14 days. - Participation in other studies involving interventional studies within 28 days prior to study entry (<28 days) and/or during study participation. - Other circumstances that, in the judgment of the investigator, make participation in this clinical trial inappropriate. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
CanSino Biologics Inc. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Meningococcal antibody positive conversion rates for groups A, C, Y, and W135 in all subjects | 30 days post immunization | ||
Primary | Geometric mean titer (GMT) of antibodies to groups A, C, Y, and W135 in all subjects | 30 days post immunization | ||
Primary | Incidence of adverse reactions in all subjects | Within 30 mins after immunization | ||
Primary | Incidence of adverse reactions/events in all subjects | 7 days post immunization | ||
Primary | Incidence of adverse reactions/events in all subjects | Within 30 days after immunization | ||
Secondary | Meningococcal antibody positivity for groups A, C, Y, and W135 | 30 days post immunization | ||
Secondary | Geometric mean multiplicity (GMI) of increase for groups A, C, Y, and W135 | 30 days post immunization | ||
Secondary | Antibody titer =1:128 ratio for groups A, C, Y, and W135 | 30 days post immunization | ||
Secondary | Meningococcal antibody positivity for groups A, C, Y, and W135 in selected subjects | 180 days after immunization | ||
Secondary | GMT for groups A, C, Y, and W135 in selected subjects | 180 days after immunization | ||
Secondary | GMI for groups A, C, Y, and W135 in selected subjects | 180 days after immunization | ||
Secondary | Antibody titer =1:128 ratio for groups A, C, Y, and W135 in selected subjects | 180 days after immunization | ||
Secondary | Incidence of serious adverse events (SAEs) in all subjects | Within 180 days after immunization | ||
Secondary | Incidence of pregnancy events in all subjects | Within 180 days after immunization |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01434680 -
Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers
|
Phase 2 | |
Completed |
NCT01424644 -
A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents
|
Phase 4 | |
Completed |
NCT00384397 -
A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers
|
Phase 3 | |
Completed |
NCT01453348 -
Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine
|
Phase 3 | |
Completed |
NCT01214837 -
Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life
|
Phase 3 | |
Completed |
NCT00874549 -
Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years
|
Phase 1/Phase 2 | |
Completed |
NCT00355121 -
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
|
Phase 2 | |
Completed |
NCT02591290 -
Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects
|
Phase 4 | |
Completed |
NCT01717638 -
Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1
|
Phase 3 | |
Completed |
NCT01482052 -
Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis
|
Phase 1 | |
Completed |
NCT01466387 -
A Phase 3b, Randomized, Open-Label Study to Evaluate the Safety and Immunogenicity of Select Travel Vaccines When Administered Concomitantly With MenACWY in Adults
|
Phase 3 | |
Completed |
NCT01239043 -
Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination
|
Phase 2 | |
Completed |
NCT00994695 -
Safety, Immunogenicity and Reactogenicity Trial of Mencevax ACW135 Vaccine
|
Phase 2 | |
Completed |
NCT01732627 -
Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older
|
Phase 2 | |
Completed |
NCT01478347 -
A Phase 3b Study to Assess the Safety of Novartis Meningococcal B Recombinant Vaccine When Administered in Healthy At-risk Adults
|
Phase 3 | |
Completed |
NCT00483574 -
Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers
|
Phase 3 | |
Completed |
NCT00474487 -
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults
|
Phase 3 | |
Completed |
NCT03205358 -
Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Toddlers
|
Phase 2 | |
Completed |
NCT00667602 -
Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers
|
Phase 3 | |
Completed |
NCT00450437 -
A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In US Adolescents and Adults
|
Phase 3 |